Recurrent Lymphoepithelioma of the Nasopharynx Completed Phase 1 Trials for Alvespimycin (DB12442)

IndicationStatusPhase
DBCOND0029500 (Recurrent Lymphoepithelioma of the Nasopharynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00089362Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsTreatment